Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Radiotherapy for Pediatric Tumors
share announcement

Radiotherapy for Pediatric Tumors

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Childhood, Adolescent and Young Adult Oncology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2753

Special Issue Editors

Dr. Kevin X. Liu

E-Mail Website
Guest Editor
Department of Radiation Oncology, Brigham and Women’s Hospital, Dana‐Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Interests: neuroblastoma; pediatric brain tumors; pediatric cancers; pediatric sarcomas; stereotactic body radiation therapy; stereotactic radiosurgery; translational clinical trials
Dr. Nicholas DeNunzio

E-Mail Website
Guest Editor
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
Interests: brain and spine tumors; gastrointestinal tumors; sarcomas; pediatrics; proton therapy; radiosurgery

Special Issue Information

Dear Colleagues,

Radiotherapy plays an important role in the treatment of many pediatric tumors. Radiation treatment can improve local control and is critical in curing certain types of pediatric malignancies. Furthermore, radiotherapy can help palliative symptoms after tumor recurrence and address oligometastatic or oligoprogressive disease. However, radiation can lead to acute and long-term toxicity, some of which can be morbid, especially for pediatric patients. In recent decades, advances in radiation technology and planning have contributed to improvements in outcomes, including the reduction in toxicity. Future research is underway to investigate new strategies to improve local control and survival in pediatric tumors with poor prognosis and decrease acute and long-term toxicity after radiation.

This Special Issue brings together leading experts and researchers to discuss various aspects of radiotherapy for pediatric tumors. This Special Issue will seek to explore interesting and challenging questions from a wide range of topics, including, but not limited to, the following: clinical outcomes after radiotherapy, including toxicity; the development of novel radiotherapy treatment paradigms; preclinical research to identify new radiosensitizers; and long-term survivorship care after radiation treatment within the context of pediatric tumors. Together, this Special Issue will serve as a valuable resource for clinicians, researchers, and healthcare professionals involved in the care of pediatric patients with tumors, and it will aim to foster the development of novel treatment strategies and improve the quality of life for these young patients. In this Special Issue, original research articles and reviews are welcome.

Dr. Kevin X. Liu
Dr. Nicholas DeNunzio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric tumors
  • radiotherapy
  • proton radiotherapy
  • photon radiotherapy
  • brachytherapy
  • stereotactic body radiotherapy
  • stereotactic radiosurgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 515 KiB  
Article
Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
by Ellery Koelker-Wolfe, Karen J. Marcus, Steven G. DuBois, Paul J. Catalano, Suzanne Shusterman, Myrsini Ioakeim-Ioannidou, Hesham Elhalawani, Torunn I. Yock, Shannon M. MacDonald, Daphne A. Haas-Kogan and Kevin X. Liu
Curr. Oncol. 2025, 32(3), 124; https://doi.org/10.3390/curroncol32030124 - 22 Feb 2025
Viewed by 532
Abstract
Introduction: While palliative radiotherapy (RT) is frequently used in the management of relapsed/refractory high-risk neuroblastoma (HR-NBL); outcomes after palliative hypofractionated RT (hypo-RT) remain poorly characterized. Methods: We conducted a multi-institutional retrospective study of 38 patients who were diagnosed with HR-NBL between 1997 [...] Read more.
Introduction: While palliative radiotherapy (RT) is frequently used in the management of relapsed/refractory high-risk neuroblastoma (HR-NBL); outcomes after palliative hypofractionated RT (hypo-RT) remain poorly characterized. Methods: We conducted a multi-institutional retrospective study of 38 patients who were diagnosed with HR-NBL between 1997 and 2021 and received palliative RT. Conventional RT (conv-RT) and hypo-RT were defined as palliative treatment courses using dose ≤2 or >2 Gy per fraction, respectively. The primary outcome was cumulative incidence of in-field progression using Gray’s test. Univariate analyses were performed using the Cox proportional hazards model. Results: When analyzing by first course of palliative RT, 16 patients received conventionally fractionated RT (43%) and 21 received hypo-RT (57%). Clinical characteristics were similar between the two groups. With a median follow-up of 10.3 months (range: 0.3–104.0), the cumulative incidence of in-field progression was not statistically significantly different between hypo-RT and conv-RT (30% vs. 20% at 10 months; p = 0.80). Clinical response, defined as symptomatic improvement or decrease in the size of the lesion, was not statistically different between the two groups (92% conv-RT vs. 90% hypo-RT; p = 1.00). No grade ≥4 toxicities were observed. On univariate analysis, hypo-RT (HR 1.50; 95% CI 0.47–4.76; p = 0.493) was not statistically significantly associated with time to in-field progression, but MYCN amplification was associated with significantly longer time to in-field progression (HR: 0.20; 95% CI: 0.05–0.77; p = 0.020). Conclusions: We found no statistically significant difference in cumulative incidence of in-field progression and clinical outcomes between the conv-RT and hypo-RT groups. Palliative hypo-RT can be considered for relapsed/refractory HR-NBL, especially when shorter treatments may offer improved quality of life. Full article
(This article belongs to the Special Issue Radiotherapy for Pediatric Tumors)
►▼ Show Figures

Figure 1

13 pages, 3956 KiB  
Communication
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
by Célia Gotorbe, Fabien Segui, William Echavidre, Jérôme Durivault, Thays Blanchard, Valérie Vial, Marina Pagnuzzi-Boncompagni, Rémy Villeneuve, Régis Amblard, Nicolas Garnier, Cécile Ortholan, Benjamin Serrano, Vincent Picco, Jacques Pouysségur, Milica Vucetic and Christopher Montemagno
Curr. Oncol. 2024, 31(11), 7390-7402; https://doi.org/10.3390/curroncol31110545 - 20 Nov 2024
Cited by 1 | Viewed by 1540
Abstract
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death [...] Read more.
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death induced by ROS and inhibited by antioxidants such as cysteine, glutathione (GSH), and glutathione peroxidase 4 (GPx4). However, the link between αvβ3 expression, ferroptosis inhibition, and sensitivity to radiotherapy remains unclear. We showed that irradiated β3_KO medulloblastoma cells primarily die by ferroptosis, with β3-subunit expression correlating with radiotherapy sensitivity and anti-ferroptotic protein levels. Our findings suggest that integrin-αvβ3 signaling boosts oxidative stress resilience via mTORC1. Thus, targeting integrin-αvβ3 could enhance radiotherapy efficacy in medulloblastoma by inducing ferroptotic cell death. Full article
(This article belongs to the Special Issue Radiotherapy for Pediatric Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop